Will rasagiline be included in medical insurance coverage in 2025?

Rasagiline is a monoamine oxidase B (MAO-B) inhibitor used in the treatment of Parkinson's disease (PD). The drug improves motor dysfunction by inhibiting the metabolism of dopamine in neurons and prolonging its action time at synapses. In China, rasagiline has been approved by the State Food and Drug Administration and officially launched on the market as an auxiliary or single drug option in the treatment of Parkinson's disease. According to the adjustment results of the latest version of the National Medical Insurance Directory, rasagiline has been included in the scope of basic medical insurance drugs.

In the specific description of the medical insurance coverage, rasagiline is classified as a Class B drug and is suitable for second-line use in Parkinson's disease, which means that it is mainly used for patients with poor or fluctuating levodopa treatment effects. According to medical insurance regulations, patients must have a prescription issued by a secondary medical institution and above and meet relevant diagnostic standards before they can enjoy the medical insurance reimbursement policy. The medical insurance payment ratio, threshold and reimbursement amount depend on the specific policies of each province and city, which are usually around 70%. However, there may be slight differences in different regions. It is recommended that patients directly consult the local medical insurance department or hospital pharmacy department to obtain accurate information.

It is worth noting that because Parkinson's disease is more common in the elderly, these patients have a heavier financial burden. After rasagiline is included in medical insurance, it effectively lowers the economic threshold for chronic medication and improves treatment compliance. Currently, the main products sold in China are versions of original drugs produced by imported pharmaceutical companies, which have reliable efficacy, low side effects, and good tolerance in long-term treatment. With the continuous optimization of the medical insurance payment mechanism, rasagiline's use coverage and accessibility will gradually increase, and it is expected to become one of the important treatment options for Chinese Parkinson's patients.

Reference materials:https://www.azilect.com/